Protein Sciences (PSC) has started manufacturing vaccine against the H1N1(Swine flu) virus. The company has estimated to produce 100,000 doses this week, and will continue with the same figure per week thereafter.
The vaccine, PanBlok, is developed by using PSC’s proprietary baculovirus and insect cell manufacturing technology.
The vaccine will undergo routine quality tests, the longest of which will require up to one month. Thus, by mid-July, the vaccine should be ready to be used in clinical trials and/or for vaccinations in countries that grant regulatory clearance, said the company.
PSC is in late stage discussions with various parties in the US and abroad to conduct the first human clinical trials of the vaccine.
Daniel Adams, Chairman, President and CEO of PSC, said: “We are in the process of transferring our proprietary manufacturing technology to facilities in other countries and we are setting up a foundation to ensure vaccine availability for UN member countries consistent with the commitment we made to the World Health Organization and the United Nations in Geneva, Switzerland on May 19, 2009.”